Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.

Treatment involved an antithrombin-based dose regimen targeting antithrombin levels between 15% and 35%, starting at 50 mg once every 2 months, individually adjusted to 20, 50, or 80 mg monthly or 20 ...

Novo Nordisk NVO shares have lost 21% in the past three months against the industry’s growth of 4.6%. The company has also ...

Martin Holst Lange, Executive Vice President, Development, Novo Nordisk, highlighted during the press briefing that their ...

Still, Novo is steadfast in its goal to eventually become a leader in the space, the company’s EVP of rare disease, Ludovic ...

New treatments have changed the face of managing hemophilia with an inhibitor, columnist Cazandra Campos-MacDonald writes.

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

Citing that there is unmet medical need in the country for the proposed indication, the Subject Expert Committee (SEC) ...

(Bloomberg) -- A long-term Novo Nordisk A/S skeptic recommended buying shares of the Danish weight-loss drug maker nine years after starting coverage of the stock. Kepler Cheuvreux’s David Evans ...

NovoCare also lists Novo Nordisk diabetes products as well as the pharma giant’s drugs for growth-related disorders, hemophilia, and hyperoxaluria. “Today, over 55 million people in the U.S ...

Shares of Novo Nordisk slipped in Monday morning trading after the company announced results of its latest weight-loss drug trial. Novo's results from its Redefine 2 late-stage trial of ...